Hey TC for the Town Hall tomorrow…

Quote
Anonymous said:
The stock was a roller coaster when HR ran it. And he tried desperately to sell the company before retiring but obviously didn't have success. Sure, you can call Proteolix luck, but you can also easily call it savvy deal-making. Also, the subtle genius of the Bayer deal, which clearly went over your head, was the removal of the change of control clause (translation - it allowed other potential buyers to look at Onyx more seriously because they wouldn't have to worry about the rights to Nexavar and Stivarga reverting back to Bayer). And in what planet is a 20% royalty on a $1 billion+ drug considered a failure? That's straight to the bottom line with no costs associated with it. You do realize that the economics are similar to the 50-50 profit split on Nexavar, right? In the latter case, the costs are baked into the numbers reported by Onyx, which is the reason it seems lower than 50%. And if you include the removal of the Japan royalty, that translates into roughly 20% straight to Onyx's bottom line.
Click to expand...


Look clearly your not a finance guy but 50% of a billion dollar drug with declining costs over the life cycle is a better deal than 20% with no overhead...the change of control could have been negotiated at anytime for a variety of reasons...tC and SS got outclassed in that deal and every biotech analysts said so. Stop being TC apologist...the stock got to $100 organically. So he really didn't negotiate crap. Amgen is lauging all the way to the bank!
 






Anonymous said:
Look clearly your not a finance guy but 50% of a billion dollar drug with declining costs over the life cycle is a better deal than 20% with no overhead...the change of control could have been negotiated at anytime for a variety of reasons...tC and SS got outclassed in that deal and every biotech analysts said so. Stop being TC apologist...the stock got to $100 organically. So he really didn't negotiate crap. Amgen is lauging all the way to the bank!
Click to expand...

They got their arses handed to them!
 






Anonymous said:
4% - That's what TC got us. Thank god he had sense enough to take the offer this week, if we'd come back after the Labor Day weekend with no deal the stock would have been trading at $110 and we would have had to settle for $118.
Way to go TC, you're a #1 negotiasturbator.
Click to expand...

Agreed, must be some bad signs in the data Amgen requested, we're lucky to get $125.
 


















Anonymous said:
Look clearly your not a finance guy but 50% of a billion dollar drug with declining costs over the life cycle is a better deal than 20% with no overhead...the change of control could have been negotiated at anytime for a variety of reasons...tC and SS got outclassed in that deal and every biotech analysts said so. Stop being TC apologist...the stock got to $100 organically. So he really didn't negotiate crap. Amgen is lauging all the way to the bank!
Click to expand...

So I'm a TC apologist just because I'm making an argument? I guess we're resorting to playground tactics now. And how are you not a Wall Street apologist then? I am dumbfounded that you think we got to $100 "organically". You seriously think we could've done it without Proteolix and the Bayer settlement - both TC wins? You think just having 50% of Nexavar would've brought us there, I guess, even though the stock was languishing in the 30s for years.

I think your knowledge of finance not as good as you think. I'm arguing that at best, we could've gotten 50% profit-split for Stivarga (same as the original Nexavar deal), which is almost the same as 20% with no costs. Free finance lesson for you: profit = revenue - cost. And, oh great negotiator, how was the change of control going to be negotiated at any time? Was Bayer going to give it to Onyx for free and out of the goodness of its heart? Grow up and be happy with your profits!
 






Top Bottom
Back
Quote